Phenotype Switching in Melanoma: Implications for Progression and Therapy

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression

(2014) G Denecker et al.   CELL DEATH AND DIFFERENTIATION

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

(2014) Jamie N. Anastas et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

(2014) Xiao-Hong Ma et al.   JOURNAL OF CLINICAL INVESTIGATION

Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

(2014) T. J. Parmenter et al.   Cancer Discovery

Melanoma Cells Revive an Embryonic Transcriptional Network to Dictate Phenotypic Heterogeneity

(2014) Niels Vandamme et al.   Frontiers in Oncology

The Emerging Role of Exosomes in Epithelial–Mesenchymal-Transition in Cancer

(2014) Laura Jayne Vella   Frontiers in Oncology

Directed Phenotype Switching as an Effective Antimelanoma Strategy

(2013) Magalí Sáez-Ayala et al.   CANCER CELL

A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma

(2013) Julie Caramel et al.   CANCER CELL

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence

(2013) Joanna Kaplon et al.   NATURE

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)

(2013) R Y-J Huang et al.   Cell Death & Disease

Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

(2013) M. P. O'Connell et al.   Cancer Discovery

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

(2012) Sidong Huang et al.   CELL

Epidermal Growth Factor Facilitates Melanoma Lymph Node Metastasis by Influencing Tumor Lymphangiogenesis

(2012) Andreas Bracher et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

(2012) Héctor Peinado et al.   NATURE MEDICINE

The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion

(2012) Nina Fenouille et al.   PLoS One

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

Transcriptional Activation of ZEB1 by Slug Leads to Cooperative Regulation of the Epithelial–Mesenchymal Transition-Like Phenotype in Melanoma

(2011) Christian Wels et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching

(2011) Ossia M. Eichhoff et al.   Pigment Cell & Melanoma Research

Green Tea Catechins Reduce Invasive Potential of Human Melanoma Cells by Targeting COX-2, PGE2 Receptors and Epithelial-to-Mesenchymal Transition

(2011) Tripti Singh et al.   PLoS One

 -catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness

(2011) E. Sanchez-Tillo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways

(2010) Naoko Takebe et al.   Nature Reviews Clinical Oncology

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators

(2010) Petra Koefinger et al.   Pigment Cell & Melanoma Research

Cancer stem cells versus phenotype-switching in melanoma

(2010) Keith S. Hoek et al.   Pigment Cell & Melanoma Research

Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells

(2009) Chie Kudo-Saito et al.   CANCER CELL

Epithelial-Mesenchymal Transitions in Development and Disease

(2009) Jean Paul Thiery et al.   CELL

Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma

(2009) Ramin Massoumi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH

Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis

(2008) Jing Yang et al.   DEVELOPMENTAL CELL

The advantage of women in cancer survival: An analysis of EUROCARE-4 data

(2008) A. Micheli et al.   EUROPEAN JOURNAL OF CANCER

Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism

(2008) Georgia Chalkiadaki et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF

(2008) Claudia Wellbrock et al.   PLoS One